Serum CCL17 level becomes a predictive marker to distinguish between mild/moderate and severe/critical disease in patients with COVID-19

Sugiyama, Masaya; Iwamoto, Noriko; Ide, Satoshi; Nomoto, Hidetoshi; Nakamoto, Takato; Saito, Sho; Ishikane, Masahiro; Kutsuna, Satoshi; Hayakawa, Kayoko; Hashimoto, Masao; Suzuki, Manabu; Izumi, Shinyu; Hojo, Masayuki; Tsuchiya, Kiyoto; Gatanaga, Hiroyuki; Jin, Tao; Usami, Masahide; Kano, Toshikazu; Yanai, Hidekatsu; Nishida, Nao; Kanto, Tatsuya; Sugiyama, Haruhito; Ohmagari, Norio; Mizokami, Masashi

doi:10.1016/j.gene.2020.145145

Cited by 76 publications

(85 citation statements)

References 42 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, CCL17 levels in common diseases (negative for SARS-CoV-2 RNA) including chronic hepatitis C, type 2 diabetes mellitus, chronic renal failure, chronic heart failure, interstitial pneumonia and rheumatoid arthritis were found to be higher than in COVID-19 patients at an early phase who went on to develop severe disease. The authors of this study also stated that CXCL9 and CXCL10 levels in sera surged and then suddenly dropped before the patients deteriorated and required oxygen support ( Sugiyama et al, 2021 ). These markers along with the ones mentioned previously can perhaps be used as triage markers for predicting severe disease to prioritize for early therapeutic interventions.…”

Section: Introductionmentioning

confidence: 76%

Chemokine Regulation During Epidemic Coronavirus Infection

Majumdar

Murphy

2021

Front. Pharmacol.

View full text Add to dashboard Cite

SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus-2) is the third coronavirus to emerge as a cause of severe and frequently fatal pneumonia epidemics in humans, joining SARS-CoV and MERS-CoV (Middle East Respiratory Syndrome-coronavirus). As with many infectious diseases, the immune response to coronavirus infection may act as a double-edged sword: necessary for promoting antiviral host defense, but, if not appropriately regulated, also able to incite life-threatening immunopathology. Key immunoregulatory mediators include the chemokines, a large family of leukocyte chemoattractants that coordinate leukocyte infiltration, positioning and activation in infected tissue by acting at specific G protein-coupled receptors. Here, we compare the involvement of chemokines and chemokine receptors during infection with the three epidemic coronaviruses and discuss their potential value as biomarkers and targets for therapeutic development.

show abstract

Section: Introductionmentioning

confidence: 76%

Chemokine Regulation During Epidemic Coronavirus Infection

Majumdar

Murphy

2021

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Immune system hyperactivation and paralysis reportedly drive immunopathology in severe COVID-19 ( Kalfaoglu et al, 2020 ). Sugiyama et al reported that serum CCL17 level offers a predictive marker for distinguishing between mild/moderate and severe/critical disease in patients with COVID-19 ( Sugiyama et al, 2020 ). From our data, only sIL2R levels ≥ 1060 U/ml correlated significantly with mortality in multivariate logistic regression analysis based on the results of univariate analyses.…”

mentioning

confidence: 99%

Soluble interleukin-2 receptor levels on admission associated with mortality in coronavirus disease 2019

Kaya

Kaji

Usuda

2021

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Objectives Early and simple detection of high-risk groups is crucial to minimizing severe coronavirus disease 2019 (COVID-19)-related death, and soluble interleukin 2 receptor (sIL2R) has been suspected to offer a prognostic marker for infectious diseases. We validated the usefulness of sIL2R as a marker for the related deaths. Methods This retrospective observational study enrolled participants who showed positive results for severe acute respiratory syndrome coronavirus 2 RNA admitted to our hospital between April 1 and September 30, 2020. Of the 102 patients enrolled in this study, sIL2R levels were measured in 87 patients. For comparisons between survival and non-survival groups, potential confounding variables were entered into univariate models, and variables showing significant correlations ( p < 0.05) in those models were added to a multivariate model. Results Age ≥60 years and sIL2R level ≥1060 U/ml were significantly associated with mortality in univariate analyses. Only sIL2R level correlated significantly with mortality on multivariate logistic regression analysis. Further, sequential sIL2R levels in 3 patients were increased at progression or death. Conclusion SIL2R on admission and sequential monitoring of sIL2R might reflect disease severity.

show abstract

“…TRAIL has previously been correlated with viral load during SARS-CoV-2 infection 10 , but we found it to be significantly decreased in the serum of RSV and SARS-CoV-2 patients compared to healthy donors in our cohort (Figure 5B). Additionally, CCL17 and CCL22, chemokines known to be involved in the mobilization of immune cell to the lungs 45,46 and reported to be increased in SARS-CoV-2 infection 10,47,48 , were decreased or unchanged in the serum compared to healthy donors in our cohort. These findings are most likely due to the timing of the sample collection from symptom onset; studies have shown that trafficking of immune cells by these chemokines are most elevated as early as 1 week after infection 47 , and since all of our samples came from hospitalized patients, some were collected weeks after symptom onset (Table 1).…”

Section: Pro-inflammatory Cytokines and Chemokines Are Increased Durimentioning

confidence: 57%

A differential regulatory T cell signature distinguishes the immune landscape of COVID-19 hospitalized patients from those hospitalized with other respiratory viral infections

Vick

Frutoso

Mair

et al. 2021

Preprint

View full text Add to dashboard Cite

SARS-CoV-2 infection has caused a lasting global pandemic costing millions of lives and untold additional costs. Understanding the immune response to SARS-CoV-2 has been one of the main challenges in the past year in order to decipher mechanisms of host responses and interpret disease pathogenesis. Comparatively little is known in regard to how the immune response against SARS-CoV-2 differs from other respiratory infections. In our study, we compare the peripheral blood immune signature from SARS-CoV-2 infected patients to patients hospitalized pre-pandemic with Influenza Virus or Respiratory Syncytial Virus (RSV). Our in-depth profiling indicates that the immune landscape in patients infected by SARS-CoV-2 is largely similar to patients hospitalized with Flu or RSV. Similarly, serum cytokine and chemokine expression patterns were largely overlapping. Unique to patients infected with SARS-CoV-2 who had the most critical clinical disease state were changes in the regulatory T cell (Treg) compartment. A Treg signature including increased frequency, activation status, and migration markers was correlated with the severity of COVID-19 disease. These findings are particularly relevant as Tregs are being discussed as a therapy to combat the severe inflammation seen in COVID-19 patients. Likewise, having defined the overlapping immune landscapes in SARS-CoV-2, existing knowledge of Flu and RSV infections could be leveraged to identify common treatment strategies.

show abstract

Serum CCL17 level becomes a predictive marker to distinguish between mild/moderate and severe/critical disease in patients with COVID-19

Cited by 76 publications

References 42 publications

Chemokine Regulation During Epidemic Coronavirus Infection

Chemokine Regulation During Epidemic Coronavirus Infection

Soluble interleukin-2 receptor levels on admission associated with mortality in coronavirus disease 2019

A differential regulatory T cell signature distinguishes the immune landscape of COVID-19 hospitalized patients from those hospitalized with other respiratory viral infections

Contact Info

Product

Resources

About